Please login to the form below

Not currently logged in
Email:
Password:

enoxaparin

This page shows the latest enoxaparin news and features for those working in and with pharma, biotech and healthcare.

Portola rejection hands advantage to Boehringer's Pradaxa

Portola rejection hands advantage to Boehringer's Pradaxa

Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.

Latest news

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    To address some of these limitations, subcutaneously administered low molecular weight heparins (LMWHs), such as enoxaparin (Clexane/Lovenox; Sanofi), were developed. ... Results from this trial showed that LY 517717 appeared to be as effective as

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....